Clinical Trial Update: A Study of Olverembatinib in SDH-deficient GIST. [Phase 3]

View source ↗

Summary

This Phase 3 clinical trial update describes evaluating olverembatinib in SDH-deficient gastrointestinal stromal tumor (GIST) and indicates the study is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Olverembatinib (Olverembatinib)

Snippet

Sponsor: Ascentage Pharma Group Inc. | Conditions: GIST | Phase 3 | Status: RECRUITING